Wednesday, 24 July 2019

Samsung Bioepis Humira biosimilar wins FDA approval

(This story corrects to show that Hadlima belongs to Samsung Bioepis not Merck & Co Inc, which is commercializing the drug in the United States)


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)